COLL vs LMAT: fair value comparison
Collegium Pharmaceutical, Inc. and LeMaitre Vascular, Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, LMAT currently sits closer to the top of our discount ranking. LMAT carries the stronger quality grade.
| COLL | LMAT | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $35.58 | $103.61 |
| 12-month range | $31.78–$47.11 | $79.78–$111.76 |
| Sector rank | #42 of 113 Healthcare | #37 of 113 Healthcare |
| Quality grade | C- | C+ |
| Leverage | High | Low |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: COLL fair value analysis · LMAT fair value analysis